This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Social Bookmarking   What's this?

Brian Vastag

JAMA. 2001;285:399-400.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—Organizers of a large breast cancer prevention study are calling on primary care physicians to be more active in finding candidates for the trial, called STAR (Study of Tamoxifen and Raloxifene), which is seeking 22 000 postmenopausal women in whom to compare the drugs tamoxifen (Nolvadex, Astra-Zeneca) and raloxifene (Evista, Eli Lilly & Co).

Credit: National Cancer Institute

While overall recruitment is nearly on target, with some 8500 participants, many of the 500 study centers report falling short of their goals. Recruiters saythat a large part of the problem stems from physicians who have already decided that raloxifene is a better choice, despite the absence of data comparing the drugs. (Data from STAR are expected 5 years after total enrollment.)

Each STAR participant will take two pills daily; one is the study drug (either raloxifene or tamoxifen) and one is a placebo. (Raloxifene pills and placebos are oval; . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Raloxifene for Breast Cancer Prevention
Leo Plouffe, Jr and Brian Vastag
JAMA. 2001;285(16):2079.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Raloxifene for Breast Cancer Prevention
Plouffe and Vastag
JAMA 2001;285:2079-2079.
FULL TEXT